このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

ASLAN Pharmaceuticals マネジメント

マネジメント基準チェック /14

ASLAN Pharmaceuticals'の CEO はCarl Alan Jason Firthで、 Jan2010年に任命され、の在任期間は 14.42年です。は、会社の株式の0.62%を直接所有しており、その価値は$ 50.35K 。経営陣と取締役会の平均在任期間はそれぞれ7.6年と2.8年です。

主要情報

Carl Alan Jason Firth

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	14.5yrs
CEOの所有権	0.6%
経営陣の平均在職期間	7.7yrs
取締役会の平均在任期間	2.8yrs

経営陣の近況

Recent updates

ASLAN Pharma to start trial of eczema drug in patients with a previous treatment

Sep 14

ASLAN Pharmaceuticals receives DMC nod for ASLAN004 trial expansion cohort

Jan 11

CEO（最高経営責任者

Carl Alan Jason Firth (51 yo)

14.5yrs

在職期間

Dr. Carl Alan Jason Morton Firth, EMBA, Ph D., serves as Chief Executive Officer of ASLAN Pharmaceuticals Limited since January 2011. Dr. Firth served as the President of ASLAN Pharmaceuticals Limited.He...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Carl Alan Jason Firth	Founder	14.5yrs	データなし	0.62% $ 41.6k
Kiran Kumar Asarpota	COO & Head of Finance	13.7yrs	データなし	0.020% $ 1.4k
Ben Goodger	General Counsel	7.7yrs	データなし	0.023% $ 1.6k
Stephen Doyle	Chief Business Officer	6.4yrs	データなし	0.011% $ 737.8
Alexandre Kaoukhov	Chief Medical Officer	2.3yrs	データなし	0% $ 0
Charlie Hsu	Investor Relations Director	no data	データなし	データなし
Chi-Chin Wang	IR & Corporate Development Director	no data	データなし	データなし

7.7yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: ASLNの経営陣は経験豊富で経験豊富です（平均在職期間は7.6年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Carl Alan Jason Firth	Founder	14yrs	データなし	0.62% $ 41.6k
Robert Hoffman	Independent Non-Executive Director	5.8yrs	US$63.25k	0.027% $ 1.8k
Neil Graham	Independent Director	3.4yrs	US$66.29k	0% $ 0
Lawrence F. Eichenfield	Chairman of Scientific Advisory Board	2.8yrs	データなし	データなし
Andrew Howden	Independent Chairman	8.3yrs	US$92.38k	0.19% $ 12.6k
Reynold A. Panettieri	Scientific Advisor	less than a year	データなし	データなし
Kathleen M. Metters	Independent Director	3.3yrs	US$58.50k	0% $ 0
Eric Simpson	Member of Scientific Advisory Board	2.8yrs	データなし	データなし
Peter Foley	Member of Scientific Advisory Board	2.8yrs	データなし	データなし
Melinda Jennifer Gooderham	Member of Scientific Advisory Board	2.8yrs	データなし	データなし
Ramaswamy Krishnan	Scientific Advisor	less than a year	データなし	データなし

2.8yrs

平均在職期間

65.5yo

平均年齢

経験豊富なボード: ASLNの取締役会は経験豊富ではない ( 2.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

ASLAN Pharmaceuticals マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

High number of new and inexperienced directors

ASLAN Pharmaceuticals Appoints Dr. Kathleen Metters as Independent Director

ASLAN Pharmaceuticals Announces Executive Changes

Recent updates

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference

New major risk - Financial position

Aslan Pharmaceuticals to Present Additional Data from Interim Analysis of Trek-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

ASLAN Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of $5 million.

ASLAN Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of $5 million.

ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

ASLAN Pharmaceuticals Limited Announces New Translational Data on Eblasakimab in COPD

High number of new and inexperienced directors

New major risk - Market cap size

New minor risk - Share price stability

ASLAN Pharmaceuticals Limited Presents New Data on Eblasakimab in Atopic Dermatitis and Copd Translational Models At the 7Th Dermatology Drug Development Summit

New major risk - Negative shareholders equity

ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

ASLAN Pharmaceuticals Presents New Data from Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker

New major risk - Financial position

Aslan Pharmaceuticals Limited Announces Phase 2B Treatment of Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2B Study in Atopic Dermatitis

Aslan Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab's Unique Mechanism of Action in the Treatment of Atopic Dermatitis

Price target decreased by 8.6% to US$16.00

Aslan Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients

Price target increased to US$5.50

Aslan Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking E-Posters At the 51St Annual European Society for Dermatological Research Meeting

Price target increased to US$5.50

ASLAN Pharmaceuticals Limited Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

ASLAN Pharma to start trial of eczema drug in patients with a previous treatment

Price target decreased to US$5.50

ASLAN Pharmaceuticals Limited Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting

Aslan Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation At the 2022 Society for Investigative Dermatology Annual Meeting

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting

ASLAN Pharmaceuticals Limited Screens the First Patient in Its Phase 2B Dose-Ranging Clinical Study of Eblasakimab in Adults with Moderate-To-Severe Atopic Dermatitis

ASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology Conferences

ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

ASLAN Pharmaceuticals Limited announced that it expects to receive SGD 45 million in funding from K2 HealthVentures

ASLAN Pharmaceuticals Appoints Dr. Kathleen Metters as Independent Director

ASLAN Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of $60 million.

ASLAN Pharmaceuticals Limited announced that it expects to receive $17.999999 million in funding from Vivo Capital, LLC, Citadel Enterprise Americas LLC

ASLAN Pharmaceuticals Announces Executive Changes

ASLAN Pharmaceuticals Limited Announces New Data from a Study Conducted by University of Liverpool, UK

ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial

ASLAN Pharmaceuticals receives DMC nod for ASLAN004 trial expansion cohort

Aslan Pharmaceuticals Limited Announces Clinical Development of Aslan004

ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions

ASLAN Pharmaceuticals Limited Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study

ASLAN Pharmaceuticals Limited(GTSM:6497) dropped from S&P Global BMI Index

ASLAN Pharmaceuticals Announces Move of its Primary Listing to Nasdaq and Delisting From Taipei Exchange

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14